Literature DB >> 2941144

Proliferative and cytotoxic responses of human peripheral blood lymphocytes to autologous malignant effusions. An analysis at the clonal level.

T E Roberts, U Shipton, M Moore.   

Abstract

Peripheral blood lymphocytes from five patients were stimulated initially in mixed lymphocyte:tumour culture (MLTC) with autologous malignant effusions and cloned by limiting dilution in interleukin-2 prior to phenotyping and assay for different functional capabilities namely proliferative responsiveness to autologous and allogeneic tumours in the primed lymphocyte test (PLT) and cytotoxicity (CTX) toward a range of fresh tumour and cell line targets. For individual clones the two functional activities tended to be mutually exclusive. Clones (or 'cloids' containing more than one PLT precursor) from three of four tumours analysed were responsive to autologous tumour cells in the PLT of which two shared antigens with allogeneic tumours of similar tissue provenance. All phenotyped PLT positive clones were T3+T4+T8-. Cytotoxic clones were generated from all MLTCs. Their target cell repertoire (based on an analysis of greater than 30) was generally broad including cell lines sensitive to natural killer (NK) cells, and less frequently and to a weaker extent, fresh autologous and allogeneic tumours. An ovarian carcinoma was exceptional, insofar as the CTX of 8/9 clones was apparently restricted to the autologous tumour. Phenotypically cytotoxic clones were T3+T4-T8+, less usually T3+T4+T8-, but invariably B73.1- (a monoclonal antibody reactive with the peripheral blood NK subset). Analysis at the clonal level emphasises the diversity of responses to putative human tumour-associated antigens, and the need to identify the critical functionally active molecules in the MLTC.

Entities:  

Mesh:

Year:  1986        PMID: 2941144     DOI: 10.1007/bf00199123

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  On getting a T-cell clone and being assured you have one.

Authors:  F Bach
Journal:  Immunol Today       Date:  1983-09

2.  Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course. I. Evaluation of 46 patients with sarcoma.

Authors:  F Vánky; J Willems; A Kreicbergs; T Aparisi; M Andréen; L A Broström; U Nilsonne; E Klein; G Klein
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

4.  DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells.

Authors:  F Vánky; E Klein; J Willems
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  A clonal analysis of human peripheral blood lymphocytes displaying natural killer-like activity.

Authors:  K Roberts; M Moore
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

6.  Lysis of fresh human tumour cells by autologous tumour-associated lymphocytes: two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour.

Authors:  A Uchida; M Moore
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells.

Authors:  S Ferrini; R Biassoni; A Moretta; M Bruzzone; A Nicolin; L Moretta
Journal:  Int J Cancer       Date:  1985-09-15       Impact factor: 7.396

8.  The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.

Authors:  D Taramelli; G Fossati; A Balsari; R Marolda; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

9.  Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; A K Bhan
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

10.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  4 in total

1.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.

Authors:  M Munzarová; D Zemanová; J Kovarík; Z Pacovský; A Rejthar; J Bártek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 3.  Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.

Authors:  B M Vose
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.

Authors:  J Kan-Mitchell; P E Liggett; W Harel; L Steinman; T Nitta; J R Oksenberg; M R Posner; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.